Screening Libraries
| Cat. | Size | Price | Stock | |
| P20291 | 1mg/well * 5 Compounds | Inquiry | In stock | Contact Us |
| P20291 | 100uL/well (10mM solution) * 5 Compounds | Inquiry | In stock |
| manager@chemfaces.com | |
| Tel | (0086)-27-8423-7683 |
| Shelf Life | (0086)-27-84254680 |
| Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
| Container | 96 Well Format Sample |
| Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
| Shelf Life | 24 months (2-8 °) |
| Intended Use | For research use only. Not for human use. Not sell to patients |
| 1. The products in the ChemFaces screening libraries are all from plants. |
| 2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
| 3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
| 4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
| 5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
| Catalog No. | Information |
| CFN99858 | Loganin Loganin is a non-competitive inhibitor of BACE1 with IC50 of 47.97 μM an also inhibits AChE and BChE with IC50 values of 3.95 μM and 33.02 μM, respectively. Loganin has neuroprotective, anti-amnesic, anti-inflammatory and anti-shock effects, it also exhibits protective effects against hepatic injury and other diabetic complications associated with abnormal metabolic states and inflammation caused by oxidative stress and advanced glycation endproduct formation. Loganin can attenuate neuroinflammatory responses through the inactivation of NF-κB by NF-κB dependent inflammatory pathways and phosphorylation of MAPK in Aβ25-35-induced PC12 cells, and can protect against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells. |
| CFN99116 | Chlorogenic acid Chlorogenic acid, a phenolic compound found ubiquitously in plants, is an antioxidant and metal chelator, it has antiviral activity by inhibiting HBV replication, it inhibits the inflammatory reaction in HSE via the suppression of TLR2/TLR9-Myd88 signaling pathways. Some derivatives of chlorogenic acid are hypoglycemic agents and may affect lipid metabolism, chlorogenic acid can improve glucose tolerance, decrease some plasma and liver lipids, and improve mineral pool distribution in vivo. |
| CFN98212 | Loganic acid Loganic acid( 0.7% solution) has a strong intraocular pressure (IOP)-hypotensive effect, it exhibits both sides effect on superoxide generation. Loganic acid also has protective effects on atherosclerosis risk factors in hypercholesterolemic rabbits, it shows significant anti-inflammatory effects decreasing TNF-α and IL-6 activity in serum. |
| CFN98130 | Strychnine Strychnine-insensitive glycine site NMDA antagonist ( R )-HA-966 have neuroprotective effects in an experimental model of Parkinson's disease. Strychnine insensitive glycine receptor has anticonvulsant properties.Strychnine can block binaural inhibition in lateral superior olivary neurons, decrease the voltage-dependent Ca2+ current of both Aplysia and frog ganglion neurons. Strychnine also has inhibitory effects on GABA- and glycine-induced responses. |
| CFN90244 | Brucine Brucine has anti-cncer activity, it can treat hepatocellular carcinoma (HCC) and inhibit the proliferation of human lung cancer cell line PC-9 mainly by blocking the cell cycle at G0/G1 via down-regulating the expression of Cyclin D1, Cyclin E. |
